Administration of an aldose reductase inhibitor, ONO-2235, to streptozotocin-diabetic mice restores reductions of DRG neuronal attachment to extracellular matrix proteins in vitro

Neuroscience Letters

Volumn 263, Issue 2-3, 1999, Pages 157-160

  Sango, Kazunori ^a   Horie, Hidenori ^b   Inoue, Shuji ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Aldose reductase inhibitor; Attachment; Diabetic neuropathy; Dorsal root ganglion neurons; Extracellular matrix proteins; In vitro

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; CELL SURFACE RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 4; EPALRESTAT; FIBRONECTIN; INTEGRIN RECEPTOR; LAMININ; SCLEROPROTEIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; HYPERGLYCEMIA; LIGAND BINDING; MOTOR NERVE CONDUCTION; MOUSE; NERVE CELL CULTURE; NERVE FUNCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; SPINAL GANGLION;

ALDEHYDE REDUCTASE; AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CELLS, CULTURED; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; GANGLIA, SPINAL; LAMININ; MICE; MICE, INBRED C57BL; NEURONS; OLIGOPEPTIDES; REFERENCE VALUES; RHODANINE; THIAZOLIDINES;

EID: 0033605516     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00133-0     Document Type: Article

References (20)

1. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46:1995;223-234.
2. Cameron N.E., Leonard M.B., Ross I.S., Whiting P.H. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia. 29:1986;168-174.
3. Clark A.E., Brugge J.S. Integrins and signal transduction pathways: the road taken. Science. 268:1995;233-239.
4. Goto Y., Hotta N., Shigeta Y., Sakamoto N., Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed. Pharmacother. 49:1995;269-277.
5. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
6. Llewelyn J.G., Thomas P.K., Mirrlees D.J. Aldose reductase activity and myo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/Ks(dB/dB)]. Metabolism. 40:1991;1084-1087.
7. Low, P.A., Nickander, K.K. and Scionti, L., Role of hypoxia, oxidative stress, and excitatory neurotoxins in diabetic neuropathy. In P.J. Dyck and P.K. Thomas (Eds.), Diabetic Neuropathy, Saunders, Philadelphia, PA, 1999, pp. 317-329.
8. Miwa I., Kanbara M., Okuda J. Improvement of nerve conduction velocity in mutant diabetic mice by aldose reductase inhibitor without affecting nerve myo-inositol content. Chem. Pharm. Bull. (Tokyo). 37:1989;1581-1582.
9. Mizisin A.P., Calcutt N.A., DiStefano P.S., Acheson A., Longo F.M. Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes. 46:1997;647-652.
10. Ng D.T.F., Lee F.K., Song Z.T., Calcutt N.A., Lee L.W., Chung S.S.M., Chung S.K. Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice. Diabetes. 47:1998;961-966.
11. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 46:1997;S82-S89.
12. Sango K., Horie H., Okamura A., Inoue S., Takenaka T. Diabetes impairs DRG neuronal attachment to extracellular matrix proteins in vitro. Brain Res. Bull. 37:1995;533-537.
13. Sango K., Horie H., Inoue S. Biophysical and biochemical features of diabetic neurons in culture: what have we learned about diabetic neuropathy? J. Periph. Nerv. Syst. 2:1997;203-211.
14. Sima A.A., Prashar A., Zhang W.X., Chakrabarti S., Greene D.A. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. J. Clin. Invest. 85:1990;1410-1420.
15. Sima, A.A., Thomas, P.K., Ishii, D. and Vinik, A., Diabetic neuropathies, Diabetologia, 40 (1997) Suppl 3:B74-77.
16. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest. 94:1994;853-859.
17. Tomlinson, D.R., Role of aldose reductase inhibitors in the treatment of diabetic polyneuropathy. In P.J. Dyck and P.K. Thomas (Eds.), Diabetic Neuropathy, Saunders, Philadelphia, PA, 1999, pp. 330-340.
18. Yagihashi S., Kamijo M., Ido Y., Mirrlees D.J. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes. 39:1990;690-696.
19. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes/Metab. Rev. 11:1995;193-225.
20. Yong V.W., Horie H., Kim S.U. Comparison of six different substrata on the plating efficiency, differentiation and survival of human dorsal root ganglion neurons in culture. Dev. Neurosci. 10:1988;222-230.